期刊文献+

可溶性Apo-1/Fas对结核性和恶性胸腔积液的鉴别诊断价值

The significance of the soluble Apo-1/Fas in serum and pleural effusion in differentiating tuberculous and malignant pleural effusion
原文传递
导出
摘要 目的 通过检测血清及胸水中可溶性Apo-1/Fas(sApo-1/Fas)的水平,探讨其对鉴别良恶性疾病的意义。方法 采用酶联免疫吸附法(ELISA)法检测50例恶性胸腔积液患者和48例结核性胸腔积液患者血清和胸水中sApo-1/Fas的含量。结果 恶性胸腔积液患者血清和胸水中sApo-1/Fas的含量分别为(16.3±2.5)μg/L、(38.6±13.5)μg/L,均明显高于结核性胸腔积液组(均P<0.05)。两组胸水/血清sApo-1/Fas比值差异有统计学意义(P<0.05)。血清sApo-1/Fas+胸水sApo-1/Fas对恶性胸腔积液诊断的敏感度为66.0%、特异度为93.8%、准确度为79.6%。结论 血清和胸水中sApo-1/Fas的测定有利于良恶性胸水的鉴别。 Objective To investigate the significance of the soluble Apo-1/Fas(sApo-1/Fas) in differentiating tuberculous and malignant pleural effusion.Methods The level of sApo-1/Fas was detected by enzyme linked immunosorbent assay(ELISA).in serum and pleural effusion of 50 cases with malignant pleural effusion and 48 cases with tuberculous pleural effusion.Results The level of sApo-1/Fas in the serum and pleural effusion of malignant pleural effusion patients were (16.3±2.5)μg/L and (38.6±13.5)μg/L,significantly higher than those of tuberculous patients with pleural effusion(all P<0.05).The difference of rates of serum and pleural effusion in malignant pleural effusion and tuberculous pleural effusion patients was significant(P<0.05).The sensitivity,specificity and accuracy of sApo-1/Fas in serum and malignant pleural effusion were 66.0% and 93.8% and 79.6%.ConclusionThe detecting of sApo-1/Fas may play some role in differentiating tuberculous and malignant pleural effusion.
出处 《中国基层医药》 CAS 2012年第15期2270-2272,共3页 Chinese Journal of Primary Medicine and Pharmacy
关键词 可溶性APO-1/FAS 恶性/结核性 胸腔积液 SApo-1/Fas Malignant/tuberculosis Pleural effusion
  • 相关文献

参考文献8

二级参考文献18

  • 1张学军 郭礼和.Study of interrelation of apoptosis and dieases [J].National Medical Journal of China(中华医学杂志),1998,78(8):565-566.
  • 2Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients [J]. Clin Cancer Res, 1999,5 (11) :3529-- 3533.
  • 3ZHANG Xue—jun,GUO Li—he(张学军,郭礼和).Study of interrelation of apoptosis and dieases[J].National Medical Journal of China(中华医学杂志),1998,78(8):565—566.(in Chinese).
  • 4Owen-Schaub L,Chan H,Cusack J C,et al. Fas and Fas ligand interactions in malignant disease [J]. Int J Oncol,2000,17(1) :5--12.
  • 5Kamihira S,Yamada Y,Hiragata Y,et al. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases [J]. Intern Med, 1997,36(3):166--170.
  • 6Wu S H,Chu J J,Chiang C D. Increased soluble Fas ligand concentration in tuberculous pleural effusion [J]. J Formos Med Assoc, 2001,100 (1) : 32-- 34.
  • 7Kayagaki N,Kawasaki A,Ebata T,et al.Metalloproteinase-mediated release of human Fas ligand[ J].J Exp Med,1995,182(6):1777 -1783.
  • 8Tanaka M,Suda T,Takahashi T,et al.Expression of the functional soluble form of human Fas ligand in activated lymphocytes[ J ].EMBO J,1995,14(6):1129-1135.
  • 9Tanaka M,Suda T,Yatomi T,et al.Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes[ J].J Immunol,1997,158(5):2303-2309.
  • 10Cheng J,Zhou T,Liu C,et al.Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule[J].Science,1994,263(5154):1759-1762.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部